Gilead Sciences CEO's pay climbed to $23.7 million
Gilead Sciences Inc. CEO Daniel O'Day's compensation rose 4.8% last year to $23.7 million — roughly $97 for every buck made ...
Gilead Sciences (NasdaqGS:GILD) Faces Shareholder Proposals As Stock Rises 5%
Gilead Sciences (NasdaqGS:GILD) has been the center of investor activism, facing several shareholder proposals, including the separation of the Chairman and CEO roles and developing a comprehensive ...
3GILD : What Analysts Are Saying About Gilead Sciences Stock
Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Gilead Sciences ...
If You Invested $100 In This Stock 20 Years Ago, You Would Have This Much Today
Buying $100 In GILD: If an investor had bought $100 of GILD stock 20 years ago, it would be worth $1,262.82 today based on a ...
PMLive5h
LEO and Reig Jofre partner to improve access to psoriasis therapy in Europe
LEO Pharma and Reig Jofre have entered into a partnership aimed at improving access to LEO’s psoriasis treatment in Europe.
ThePrint on MSN13h
No local clinical trial waiver despite change in rules, drugmakers knock on health ministry’s door
Drug regulator through executive order issued last August paved way for direct launch of certain categories of drugs approved ...
Zacks Investment Research on MSN19h
Bluebird Bio (BLUE) Reports Q4 Loss, Tops Revenue Estimates
Bluebird Bio (BLUE) came out with a quarterly loss of $23.74 per share versus the Zacks Consensus Estimate of a loss of $6.60. This compares to loss of $15.60 per share a year ago. These figures are ...
Fierce Pharma3h
Another big payday for O'Day as Gilead boosts his compensation 5% to $23.7M
Gilead CEO Daniel O’Day saw another rise in his pay in 2024, reflecting the steadily upward trajectory of the company since ...